Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Recruiting 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 2

Interventions

pembrolizumab 74Cyclophosphamide 50Cisplatin 46Nivolumab 36Radiotherapy 33Paclitaxel 33Carboplatin 31Gemcitabine 30Docetaxel 27Dexamethasone 24atezolizumab 23Doxorubicin 21Bevacizumab 21Etoposide 20Blood Specimen Collection 20Vincristine 18Magnetic Resonance Spectroscopy 18Leucovorin 18Lenalidomide 18Fluorouracil 18fludarabine 17Rituximab 17Radiosurgery 17Surveys and Questionnaires 16Oxaliplatin 16Cytarabine 16Radiation 15Ipilimumab 15palbociclib 14durvalumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × quizartinib × 90 days × Clear all
NCT04687761 2026-05-13

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

PETHEMA Foundation

Phase 1/2 Completed
113 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04107727 2026-03-24

Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)

PETHEMA Foundation

Phase 2 Completed
273 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡